Lab Models for Tracking How Peptide Hormones Break Down — Improving Doping Detection

What the researchers found

In vitro models using human liver microsomes and S9 fractions successfully generated detectable metabolites for all seven peptide hormones tested: desmopressin, TB-500, GHRP-2, GHRP-6, hexarelin, LHRH, and leuprolide. Both endopeptidase and exopeptidase activity was observed across all models.

Comparison between liver and kidney tissue models showed no significant differences in metabolite profiles. Deamidation was not observed in any of the standard models but could be induced using α-chymotrypsin. The authors concluded these in vitro systems are practical tools for forensic and clinical detection of peptide metabolites in biological fluids.

Why it matters

Peptide doping agents are notoriously hard to detect because they have very short half-lives in the blood. By mapping how these peptides break down, anti-doping laboratories can search for longer-lasting metabolites instead of the parent drug — dramatically expanding the detection window and making it harder for athletes to cheat undetected.

How the study worked

Seven peptide hormones were incubated with human liver microsomes, S9 fractions, and serum samples. The resulting metabolites were identified and compared across models. Liver and kidney tissue models were compared for differences in metabolic profiles. Deamidation was separately evaluated using α-chymotrypsin incubation. This was an in vitro laboratory study with no human subjects.

What this study cannot tell us

This was purely an in vitro study, so the metabolites observed may not perfectly reflect what happens in a living human body. The study did not establish whether the identified metabolites are actually detectable in urine or blood samples at real-world concentrations after doping use. Ethical constraints prevented direct comparison with human pharmacokinetic data for most of the peptides studied.

How to read the evidence

This is an in vitro laboratory study validating analytical methodology. While it demonstrates proof of concept for metabolite prediction, the findings have not been confirmed with in vivo pharmacokinetic data from actual doping scenarios.

When this study was published

Published in 2015, this study addressed an analytical challenge that remains relevant as peptide doping continues to grow. The specific peptides tested (TB-500, GHRPs) are still among the most commonly discussed performance-enhancing peptides today.

The bigger picture

As peptide hormones become more accessible and their performance-enhancing potential more widely known, the cat-and-mouse game between doping users and anti-doping labs intensifies. This research contributes to the analytical toolkit by providing an ethical alternative to human pharmacokinetic studies and enabling labs to predict and detect peptide metabolites without administering the drugs to volunteers.

Questions still open

• Are the metabolites identified in vitro actually detectable in athlete urine or blood samples at concentrations relevant to doping?
• How long do these metabolites persist in biological fluids compared to the parent peptides?
• Can these in vitro models be extended to newer peptide doping agents as they emerge on the market?

Common questions

Read the original research

In vitro models for metabolic studies of small peptide hormones in sport drug testing.

Journal of peptide science : an official publication of the European Peptide Society, 21(1), 1-9

Citation

Esposito, Simone; Deventer, Koen; Geldof, Lore; Van Eenoo, Peter. (2015). In vitro models for metabolic studies of small peptide hormones in sport drug testing.. Journal of peptide science : an official publication of the European Peptide Society, 21(1), 1-9. https://doi.org/10.1002/psc.2710